Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis

Neurology and Therapy

Volumn 3, Issue 2, 2014, Pages 101-112

  Suhr, Ole B ^a   Conceição, Isabel M ^b,c   Karayal, Onur N ^d   Mandel, Francine S ^d   Huertas, Pedro E ^d   Ericzon, Bo Göran ^e  

^a UMEÅ UNIVERSITY   (Sweden)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^d PFIZER INC   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Disease modification; Modified body mass index; Neurology; Tafamidis; Therapeutic use; Transthyretin amyloidosis; Transthyretin familial amyloid polyneuropathy

Indexed keywords

ALBUMIN; PLACEBO; TAFAMIDIS;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BIOPSY; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROLOGIC DISEASE; NEUROPATHY IMPAIRMENT SCORE LOWER LIMBS; NORFOLK QUALITY OF LIFE DIABETIC NEUROPATHY TOTAL QUALITY OF LIFE; NUTRITIONAL STATUS; OBESITY; OPEN STUDY; PERIPHERAL EDEMA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UNDERWEIGHT;

EID: 84977079072     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-014-0023-8     Document Type: Article

References (37)

1. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.
2. Anan I, El-salhy M, Ando Y, Terazaki H. Suhr OB: comparison of amyloid deposits and infiltration of enteric nervous system in the upper with those in the lower gastrointestinal tract in patients with familial amyloidotic polyneuropathy. Acta Neuropathol. 2001;102:227–32.
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160–84.
4. Saraiva MJ. Transthyretin mutations in health and disease. Hum Mutat. 1995;5:191–6.
5. Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB. THAOS: gastrointestinal manifestations of transthyretin amyloidosis—common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61.
6. Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology. 2001;56:431–5.
7. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG, Pinho e Costa P, de Falcao Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88–98.
8. Guirl MJ, Hogenauer C, Santa Ana CA, Porter JL, Little KH, Stone MJ, Fordtran JS. Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis. Am J Gastroenterol. 2003;98:2219–25.
9. Wixner J, Karling P, Rydh A, Hornsten R, Wiklund U, Anan I, Suhr OB. Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy. Neurogastroenterol Motil. 2012;24:e1111–568.
10. Steen L, Ek B. Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand. 1983;214:387–97.
11. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235:479–85.
12. Franz C, Hoffmann K, Hinz U, Singer R, Hund E, Gotthardt DN, Ganten T, Kristen AV, Hegenbart U, Schonland S, Hinderhofer K, Buchler MW, Schemmer P. Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis. Clin Transplant. 2013;27(Suppl 25):40–8.
13. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629–34.
14. Vyndaqel 20 mg soft capsules: Summary of product characteristics. European public assessment report. Pfizer Specialty UK Limited. Available online at URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf [Accessed 13th February 2013].
15. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92.
16. Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802–14.
17. Revising the Declaration of Helsinki: Bulletin of medical ethics 2000:9–11.
18. Kim DH, Zeldenrust SR, Low PA, Dyck PJ. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve. 2009;40:363–70.
19. Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19:104–14.
20. Coelho T, Merkies I, Vinik A, et al. Relationship between objective measures of neuropathy and quality of life in stages of severity of transthyretin familial amyloid polyneuropathy. Amyloid. 2010;17(suppl 1):138.
21. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59:1771–6.
22. Lozeron P, Theaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D. Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013;20:1539–45.
23. Suhr OB, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl. 2002;8:787–94.
24. Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov. 2012;11:185–6.
25. Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2014;19:104–14.
26. Suhr O, Danielsson A, Steen L. Bile acid malabsorption caused by gastrointestinal motility dysfunction? An investigation of gastrointestinal disturbances in familial amyloidosis with polyneuropathy. Scand J Gastroenterol. 1992;27:201–7.
27. Anan I, El-Salhy M, Ando Y, Nyhlin N, Terazaki H, Sakashita N, Suhr O. Colonic endocrine cells in patients with familial amyloidotic polyneuropathy. J Intern Med. 1999;245:469–73.
28. El-Salhy M, Suhr O, Stenling R, Wilander E, Grimelius L. Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells. Gut. 1994;35:1413–8.
29. Nyhlin N, Anan I, El-Salhy M, Ando Y, Suhr OB. Endocrine cells in the upper gastrointestinal tract in relation to gastrointestinal dysfunction in patients with familial amyloidotic polyneuropathy. Amyloid. 1999;6:192–8.
30. Anan I, El-Salhy M, Nyhlin N, Suhr OB. Liver transplantation restores endocrine cells in patients with familial amyloidotic polyneuropathy. Transplantation. 2000;70:794–9.
31. Lang K, Wikstrom L, Danielsson A, Tashima K, Suhr OB. Outcome of gastrointestinal complications after liver transplantation for familial amyloidotic polyneuropathy. Scand J Gastroenterol. 2000;35:985–9.
32. Suhr OB, Anan I, Ahlstrom KR, Rydh A. Gastric emptying before and after liver transplantation for familial amyloidotic polyneuropathy, Portuguese type (Val30Met). Amyloid. 2003;10:121–6.
33. Wixner J, Obayashi K, Ando Y, Karling P, Anan I. Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis. Amyloid. 2013;20:99–106.
34. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut. 2010;59:1716–26.
35. Matsunaga N, Anan I, Forsgren S, Nagai R, Rosenberg P, Horiuchi S, Ando Y, Suhr OB. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathol. 2002;104:441–7.
36. Ejskjaer NT, Bradley JL, Buxton-Thomas MS, Edmonds ME, Howard ER, Purewal T, Thomas PK, Watkins PJ. Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabet Med. 1999;16:488–95.
37. Ordog T. Interstitial cells of Cajal in diabetic gastroenteropathy. Neurogastroenterol Motil. 2008;20:8–18.